Potential of fasting c-peptide to glucose ratio and triglyceride glucose index as markers for β-cell dysfunction and insulin resistance in patients with type 2 diabetes on insulin therapy

HIGHLIGHTS

• What: The authors aim to assess β-cell function and IR in patients with type 2 diabetes on insulin therapy by fasting C-peptide to glucose ratio (FCPGR) and triglyceride glucose (TyG) index respectively to support treatment plans. The results of this study showed that most of the recruited patients were obese, had MetS, and had poor glycemic control despite using almost the maximum basal insulin dose of 0.43 (±0.26) unit/kg/day recommended by the ADA 2024 guideline. The finding of this study showed a non-significant correlation between FCPGR and the duration of T2DM . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.